Akebia Therapeutics, Inc. (AKBA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.3531 |
| Open | 0.4939 |
| Bid | 0.3930 x 1800 |
| Ask | 0.3920 x 1300 |
| Day's Range | 0.3760 - 0.4944 |
| 52 Week Range | 0.3000 - 3.9000 |
| Volume | |
| Avg. Volume | 12,389,649 |
| Market Cap | 68.059M |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8870 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.75 |
- PR Newswire
Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical Co., Ltd. (Otsuka). As part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million.
- PR Newswire
Akebia Therapeutics to Present at Jefferies Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET. The Jefferies Healthcare Conference will take place June 8-10, 2022, in New York.
- PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 14,000 shares of Akebia's common stock on May 31, 2022, as inducements material to each such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
